Proteomics, or Protein Genomics, has been hailed as the next big opportunity in biotechnology. You ll need to understand protein function.
Genomic information is useful, but the key becomes functional relevance.
But many say the challenges in proteomics make genome mapping look like child s play. Nonetheless, a new generation of companies is emerging and investor interest is high. And pharmaceutical firms are having internal debates as to whether and how to gear up in this area. Of course the decisions most of them make will impact all of the biotech, genomic and investment firms with vested interests. Consensus is, you are going to have to be involved in this advancing field one way or another.